TRI Joins Veeva’s Product Partner Program

Partnership will drive quality and efficiency in clinical trials through enhanced risk-based quality management integration.

[Cambridge, UK – 17.10.2024] – TRI, a leading Risk-Based Quality Management (RBQM) software provider for clinical trials, today announced it has become an official Veeva Product Partner. TRI’s OPRA RBQM platform will now be integrated with Veeva Vault EDC, providing clinical trial sponsors and CROs with a powerful platform tool to capture and centrally monitor critical endpoint data.

The integration will offer a clear and streamlined approach for clinical teams to capture data in Vault EDC and a set of Fast Start RBQM dashboards, leveraging OPRA’s insights to ensure effective management of critical data. This will help reduce costs, improve safety, and ensure compliance with regulatory obligations by focusing resources on areas of greatest risk, while reducing the oversight burden elsewhere. With the integration of OPRA and Vault EDC, companies can better demonstrate evidence of clinical data oversight and more effectively address the evolving needs of clinical research.

Duncan Hall, CEO of TRI, emphasized the importance of the partnership: “As regulatory requirements become more stringent and clinical trials become more complex, companies are increasingly looking for ways to manage trial complexity whilst driving down costs and maintaining high standards of quality and compliance. The integration of OPRA with Veeva Vault EDC offers a step forward in achieving these goals. With endpoint data being the foundation of RBQM, the seamless connection between clinical databases and RBQM systems is crucial to realizing the full potential of RBQM.”